The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells

Hematology Journal

Volumn 2, Issue 4, 2001, Pages 257-264

  Pierce, A ^a   Smith, D L ^a   Jakobsen, L V ^a   Whetton, A D ^a   Spooncer, E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

BCR ABL; Haematopoietic; Inhibition; Interferon; Multipotent

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CELL CYCLE INHIBITORY PROTEIN; CELL CYCLE PROTEIN; DNA; GROWTH FACTOR; LIPOCORTIN 5; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA SYNTHESIS; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GROWTH INHIBITION; GROWTH RATE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MACROPHAGE; NEUTROPHIL; ONCOGENE; PROMYELOCYTE; STEM CELL; TEMPERATURE; WESTERN BLOTTING;

APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; STEM CELLS; TEMPERATURE;

EID: 0034888724     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200114     Document Type: Article

References (46)

1. The function of BCR/ABL and related proto-oncogenes
2. Molecular consequences of the BCR-ABL translocation in chronic myelogenous
3. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro
4. Modelling chronic myeloid leukemia
5. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1alpha, an inhibitor of primitive normal hematopoietic cells
6. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea
7. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia
8. Clinical investigation of human alpha interferon in chronic myelogenous leukemia
9. Biological basis for the clinical use of interferon
10. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha
11. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy
12. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function
13. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia
14. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells
15. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia
16. The K562 chronic myeloid leukemia cell line undergoes apoptosis in response to interferon-alpha
17. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist
18. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM
19. An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture
20. Synergistic anti-proliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM)
21. In vitro activity of alpha-interferon on granulocyte-macrophage precursors in chronic myeloid leukemia (CML)-correlation with clinical responsiveness
22. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis
23. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
24. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
25. Clonal characteristics of acute lymphoblastic cells derived from BCR/ABL p190 transgenic mice
26. Acute leukaemia in bcr/abl transgenic mice
27. Expression of p210bcr/abl by metallothionien promoter induced T-cell leukemia in transgenic mice
28. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia
29. The role of haemopoietic growth factors in self-renewal and differentiation of IL-3 dependent multipotential stem cells
30. Self-renewal and differentiation of interleukin-3-dependent multipotent stem cells are modulated by stromal cells and serum factors
31. Ectopic interleukin 5 receptor expression promotes proliferation without development in a multipotent hematopoietic cell line
32. Biological consequences of p160v-abl protein tyrosine kinase activity in a primitive, multipotent haemopoietic cell line
33. BCR/ABL mRNA and he p210(BCR/ABL) protein are down-modulated by Interferon alpha in chronic myeloid leukaemia patients
34. Alpha-interferon reduces in vivo phosphorylation of P210bcr/abl protein during hemin-induced erythroid differentiation of K-562 cells
35. Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha
36. The effect of interferon-alpha on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia
37. Differential effect of type I interferons on hematopoietic progenitor cells: Failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors
38. Growth inhibitors in haemopoiesis and leukaemogenesis
39. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines
40. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21
41. Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)
42. IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells
43. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines
44. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1
45. Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development
46. Haemopoietic stem cell development to neutrophils is associated with subcellular redistribution and differential expression of protein kinase C subspecies